Cargando…

Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer

Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuebao, Liu, Chu, Li, Kui, Wang, Ke, Zhang, Qiqiang, Cui, Yuanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/
https://www.ncbi.nlm.nih.gov/pubmed/30732140
http://dx.doi.org/10.1097/MD.0000000000014254
_version_ 1783396380649193472
author Zhang, Xuebao
Liu, Chu
Li, Kui
Wang, Ke
Zhang, Qiqiang
Cui, Yuanshan
author_facet Zhang, Xuebao
Liu, Chu
Li, Kui
Wang, Ke
Zhang, Qiqiang
Cui, Yuanshan
author_sort Zhang, Xuebao
collection PubMed
description Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated. Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P = .25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P < .001), anaemia (P < .001), thrombocytopenia (P < .001), and diarrhea (P = .002). Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo.
format Online
Article
Text
id pubmed-6380863
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63808632019-03-11 Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer Zhang, Xuebao Liu, Chu Li, Kui Wang, Ke Zhang, Qiqiang Cui, Yuanshan Medicine (Baltimore) Research Article Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated. Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P = .25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P < .001), anaemia (P < .001), thrombocytopenia (P < .001), and diarrhea (P = .002). Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo. Wolters Kluwer Health 2019-02-08 /pmc/articles/PMC6380863/ /pubmed/30732140 http://dx.doi.org/10.1097/MD.0000000000014254 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Zhang, Xuebao
Liu, Chu
Li, Kui
Wang, Ke
Zhang, Qiqiang
Cui, Yuanshan
Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
title Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
title_full Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
title_fullStr Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
title_full_unstemmed Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
title_short Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
title_sort meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/
https://www.ncbi.nlm.nih.gov/pubmed/30732140
http://dx.doi.org/10.1097/MD.0000000000014254
work_keys_str_mv AT zhangxuebao metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer
AT liuchu metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer
AT likui metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer
AT wangke metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer
AT zhangqiqiang metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer
AT cuiyuanshan metaanalysisofefficacyandsafetyofcustirseninpatientswithmetastaticcastrationresistantprostatecancer